LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis

Carlos Lahoz, José María Mostaza, Xavier Pintó, Juan José de la Cruz, José Ramón Banegas, Juan Pedro-Botet

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

© 2014 Sociedad Española de Arteriosclerosis. Objective: To evaluate low-density lipoprotein-cholesterol (LDLc) achieved in patients with genetic dyslipidemia treated during one year in Lipid and Vascular Risk Units (LVRU) of the Spanish Society of Arteriosclerosis (SSA). Design: Observational, longitudinal, retrospective, multicenter national study that included consecutive patients of both sexes over 18 years of age referred due to dyslipidemia to LVRU of the SSA. Information was collected from medical records corresponding to two visits in the lipid unit. Results: A total of 527 patients (mean age 48 years, 60.0% men) diagnosed with genetic dyslipidemia (241 with heterozygous familial hypercholesterolemia, and 286 with familial combined hyperlipidemia) were included. The mean follow-up was 12.9 months. In the last visit, 94% were taking statins, one third combined with ezetimibe, although only 41% were taking a high-intensity hypolipidemic treatment. Overall, 28.5% of patients attained an LDLc level. <. 100. mg/dL, 35.8% decreased their LDLc by >. 50%, and 53.8% achieved one of the two. Predictors of target LDLc levels in the multivariate analysis were age, smoking habit and the presence of vascular disease. Conclusion: Over half of the patients with genetic dyslipidemia followed up by LVRU of SSA achieve LDLc objectives after one year of follow-up. The use of high-intensity hypolipidemic treatment could improve these results.
Original languageEnglish
Pages (from-to)1-8
JournalClinica e Investigacion en Arteriosclerosis
Volume27
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • Ezetimibe
  • Familial combined hyperlipidemia
  • Familial hypercholesterolemia
  • Statins

Fingerprint Dive into the research topics of 'LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis'. Together they form a unique fingerprint.

Cite this